All In Biotech

Free tool

FAERS Monitor: Rybelsus

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213182 or its brand name (Rybelsus, Semaglutide). Reports on generic versions are filed under their own applications.

Reports

7,735

Serious

4,368

56% of reports

Hospitalization

1,786

Death reported

180

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea1,110
  • vomiting769
  • diarrhoea614
  • off label use484
  • decreased appetite465
  • constipation443
  • blood glucose increased372
  • weight decreased365
  • impaired gastric emptying345
  • headache325
  • fatigue313
  • dizziness305
  • abdominal pain299
  • abdominal pain upper286
  • asthenia242

Reports by year received

View as table
YearReports
20162
20171
20182
20197
2020487
2021841
20221,038
20231,065
20241,519
20251,570
20261,203

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,424 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
impaired gastric emptyingSignal34570.663.623,012
constipationSignal4435.55.11,654
decreased appetiteSignal4655.55.01,702
blood glucose increasedSignal3725.44.91,331
vomitingSignal7694.54.22,099
nauseaSignal1,1103.83.62,392
abdominal pain upperSignal2863.83.4587
weight decreasedSignal3653.63.2677
abdominal painSignal2993.53.1536
diarrhoeaSignal6142.62.4615
asthenia2421.81.578
dizziness3051.71.582
off label use4841.51.485
headache3251.41.339
fatigue3131.11.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.